Global Personalized Medicine and Epigenomics Market Size, Status and Forecast 2024-2031

Report ID: 917562 | Published Date: Sep 2024 | No. of Page: 127 | Base Year: 2023 | Rating: 4.3 | Webstory: Check our Web story
Request Sample Report
Pre-Order Enquiry
Request Discount(%) 
1 Report Overview
    1.1 Study Scope
    1.2 Market Analysis by Type
        1.2.1 Global Personalized Medicine and Epigenomics Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
        1.2.2 Reagents
        1.2.3 Kits
        1.2.4 Instruments
        1.2.5 Enzymes
        1.2.6 Services
    1.3 Market by Application
        1.3.1 Global Personalized Medicine and Epigenomics Market Share by Application: 2016 VS 2021 VS 2027
        1.3.2 Oncology
        1.3.3 Non-Oncology
        1.3.4 Cancer Drug Technology
    1.4 Study Objectives
    1.5 Years Considered

2 Global Growth Trends
    2.1 Global Personalized Medicine and Epigenomics Market Perspective (2016-2027)
    2.2 Personalized Medicine and Epigenomics Growth Trends by Regions
        2.2.1 Personalized Medicine and Epigenomics Market Size by Regions: 2016 VS 2021 VS 2027
        2.2.2 Personalized Medicine and Epigenomics Historic Market Share by Regions (2016-2021)
        2.2.3 Personalized Medicine and Epigenomics Forecasted Market Size by Regions (2022-2027)
    2.3 Personalized Medicine and Epigenomics Industry Dynamic
        2.3.1 Personalized Medicine and Epigenomics Market Trends
        2.3.2 Personalized Medicine and Epigenomics Market Drivers
        2.3.3 Personalized Medicine and Epigenomics Market Challenges
        2.3.4 Personalized Medicine and Epigenomics Market Restraints

3 Competition Landscape by Key Players
    3.1 Global Top Personalized Medicine and Epigenomics Players by Revenue
        3.1.1 Global Top Personalized Medicine and Epigenomics Players by Revenue (2016-2021)
        3.1.2 Global Personalized Medicine and Epigenomics Revenue Market Share by Players (2016-2021)
    3.2 Global Personalized Medicine and Epigenomics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
    3.3 Players Covered: Ranking by Personalized Medicine and Epigenomics Revenue
    3.4 Global Personalized Medicine and Epigenomics Market Concentration Ratio
        3.4.1 Global Personalized Medicine and Epigenomics Market Concentration Ratio (CR5 and HHI)
        3.4.2 Global Top 10 and Top 5 Companies by Personalized Medicine and Epigenomics Revenue in 2020
    3.5 Personalized Medicine and Epigenomics Key Players Head office and Area Served
    3.6 Key Players Personalized Medicine and Epigenomics Product Solution and Service
    3.7 Date of Enter into Personalized Medicine and Epigenomics Market
    3.8 Mergers & Acquisitions, Expansion Plans

4 Personalized Medicine and Epigenomics Breakdown Data by Type
    4.1 Global Personalized Medicine and Epigenomics Historic Market Size by Type (2016-2021)
    4.2 Global Personalized Medicine and Epigenomics Forecasted Market Size by Type (2022-2027)

5 Personalized Medicine and Epigenomics Breakdown Data by Application
    5.1 Global Personalized Medicine and Epigenomics Historic Market Size by Application (2016-2021)
    5.2 Global Personalized Medicine and Epigenomics Forecasted Market Size by Application (2022-2027)

6 North America
    6.1 North America Personalized Medicine and Epigenomics Market Size (2016-2027)
    6.2 North America Personalized Medicine and Epigenomics Market Size by Type
        6.2.1 North America Personalized Medicine and Epigenomics Market Size by Type (2016-2021)
        6.2.2 North America Personalized Medicine and Epigenomics Market Size by Type (2022-2027)
        6.2.3 North America Personalized Medicine and Epigenomics Market Size by Type (2016-2027)
    6.3 North America Personalized Medicine and Epigenomics Market Size by Application
        6.3.1 North America Personalized Medicine and Epigenomics Market Size by Application (2016-2021)
        6.3.2 North America Personalized Medicine and Epigenomics Market Size by Application (2022-2027)
        6.3.3 North America Personalized Medicine and Epigenomics Market Size by Application (2016-2027)
    6.4 North America Personalized Medicine and Epigenomics Market Size by Country
        6.4.1 North America Personalized Medicine and Epigenomics Market Size by Country (2016-2021)
        6.4.2 North America Personalized Medicine and Epigenomics Market Size by Country (2022-2027)
        6.4.3 United States
        6.4.4 Canada

7 Europe
    7.1 Europe Personalized Medicine and Epigenomics Market Size (2016-2027)
    7.2 Europe Personalized Medicine and Epigenomics Market Size by Type
        7.2.1 Europe Personalized Medicine and Epigenomics Market Size by Type (2016-2021)
        7.2.2 Europe Personalized Medicine and Epigenomics Market Size by Type (2022-2027)
        7.2.3 Europe Personalized Medicine and Epigenomics Market Size by Type (2016-2027)
    7.3 Europe Personalized Medicine and Epigenomics Market Size by Application
        7.3.1 Europe Personalized Medicine and Epigenomics Market Size by Application (2016-2021)
        7.3.2 Europe Personalized Medicine and Epigenomics Market Size by Application (2022-2027)
        7.3.3 Europe Personalized Medicine and Epigenomics Market Size by Application (2016-2027)
    7.4 Europe Personalized Medicine and Epigenomics Market Size by Country
        7.4.1 Europe Personalized Medicine and Epigenomics Market Size by Country (2016-2021)
        7.4.2 Europe Personalized Medicine and Epigenomics Market Size by Country (2022-2027)
        7.4.3 Germany
        7.4.4 France
        7.4.5 U.K.
        7.4.6 Italy
        7.4.7 Russia
        7.4.8 Nordic

8 Asia-Pacific
    8.1 Asia-Pacific Personalized Medicine and Epigenomics Market Size (2016-2027)
    8.2 Asia-Pacific Personalized Medicine and Epigenomics Market Size by Type
        8.2.1 Asia-Pacific Personalized Medicine and Epigenomics Market Size by Type (2016-2021)
        8.2.2 Asia-Pacific Personalized Medicine and Epigenomics Market Size by Type (2022-2027)
        8.2.3 Asia-Pacific Personalized Medicine and Epigenomics Market Size by Type (2016-2027)
    8.3 Asia-Pacific Personalized Medicine and Epigenomics Market Size by Application
        8.3.1 Asia-Pacific Personalized Medicine and Epigenomics Market Size by Application (2016-2021)
        8.3.2 Asia-Pacific Personalized Medicine and Epigenomics Market Size by Application (2022-2027)
        8.3.3 Asia-Pacific Personalized Medicine and Epigenomics Market Size by Application (2016-2027)
    8.4 Asia-Pacific Personalized Medicine and Epigenomics Market Size by Region
        8.4.1 Asia-Pacific Personalized Medicine and Epigenomics Market Size by Region (2016-2021)
        8.4.2 Asia-Pacific Personalized Medicine and Epigenomics Market Size by Region (2022-2027)
        8.4.3 China
        8.4.4 Japan
        8.4.5 South Korea
        8.4.6 Southeast Asia
        8.4.7 India
        8.4.8 Australia

9 Latin America
    9.1 Latin America Personalized Medicine and Epigenomics Market Size (2016-2027)
    9.2 Latin America Personalized Medicine and Epigenomics Market Size by Type
        9.2.1 Latin America Personalized Medicine and Epigenomics Market Size by Type (2016-2021)
        9.2.2 Latin America Personalized Medicine and Epigenomics Market Size by Type (2022-2027)
        9.2.3 Latin America Personalized Medicine and Epigenomics Market Size by Type (2016-2027)
    9.3 Latin America Personalized Medicine and Epigenomics Market Size by Application
        9.3.1 Latin America Personalized Medicine and Epigenomics Market Size by Application (2016-2021)
        9.3.2 Latin America Personalized Medicine and Epigenomics Market Size by Application (2022-2027)
        9.3.3 Latin America Personalized Medicine and Epigenomics Market Size by Application (2016-2027)
    9.4 Latin America Personalized Medicine and Epigenomics Market Size by Country
        9.4.1 Latin America Personalized Medicine and Epigenomics Market Size by Country (2016-2021)
        9.4.2 Latin America Personalized Medicine and Epigenomics Market Size by Country (2022-2027)
        9.4.3 Mexico
        9.4.4 Brazil

10 Middle East & Africa
    10.1 Middle East & Africa Personalized Medicine and Epigenomics Market Size (2016-2027)
    10.2 Middle East & Africa Personalized Medicine and Epigenomics Market Size by Type
        10.2.1 Middle East & Africa Personalized Medicine and Epigenomics Market Size by Type (2016-2021)
        10.2.2 Middle East & Africa Personalized Medicine and Epigenomics Market Size by Type (2022-2027)
        10.2.3 Middle East & Africa Personalized Medicine and Epigenomics Market Size by Type (2016-2027)
    10.3 Middle East & Africa Personalized Medicine and Epigenomics Market Size by Application
        10.3.1 Middle East & Africa Personalized Medicine and Epigenomics Market Size by Application (2016-2021)
        10.3.2 Middle East & Africa Personalized Medicine and Epigenomics Market Size by Application (2022-2027)
        10.3.3 Middle East & Africa Personalized Medicine and Epigenomics Market Size by Application (2016-2027)
    10.4 Middle East & Africa Personalized Medicine and Epigenomics Market Size by Country
        10.4.1 Middle East & Africa Personalized Medicine and Epigenomics Market Size by Country (2016-2021)
        10.4.2 Middle East & Africa Personalized Medicine and Epigenomics Market Size by Country (2022-2027)
        10.4.3 Turkey
        10.4.4 Saudi Arabia
        10.4.5 UAE

11 Key Players Profiles
    11.1 Abbott Laboratories
        11.1.1 Abbott Laboratories Company Details
        11.1.2 Abbott Laboratories Business Overview
        11.1.3 Abbott Laboratories Personalized Medicine and Epigenomics Introduction
        11.1.4 Abbott Laboratories Revenue in Personalized Medicine and Epigenomics Business (2016-2021)
        11.1.5 Abbott Laboratories Recent Development
    11.2 Affymetrix
        11.2.1 Affymetrix Company Details
        11.2.2 Affymetrix Business Overview
        11.2.3 Affymetrix Personalized Medicine and Epigenomics Introduction
        11.2.4 Affymetrix Revenue in Personalized Medicine and Epigenomics Business (2016-2021)
        11.2.5 Affymetrix Recent Development
    11.3 Agilent Technologies
        11.3.1 Agilent Technologies Company Details
        11.3.2 Agilent Technologies Business Overview
        11.3.3 Agilent Technologies Personalized Medicine and Epigenomics Introduction
        11.3.4 Agilent Technologies Revenue in Personalized Medicine and Epigenomics Business (2016-2021)
        11.3.5 Agilent Technologies Recent Development
    11.4 Astellas Pharmaceuticals
        11.4.1 Astellas Pharmaceuticals Company Details
        11.4.2 Astellas Pharmaceuticals Business Overview
        11.4.3 Astellas Pharmaceuticals Personalized Medicine and Epigenomics Introduction
        11.4.4 Astellas Pharmaceuticals Revenue in Personalized Medicine and Epigenomics Business (2016-2021)
        11.4.5 Astellas Pharmaceuticals Recent Development
    11.5 BAYER AG
        11.5.1 BAYER AG Company Details
        11.5.2 BAYER AG Business Overview
        11.5.3 BAYER AG Personalized Medicine and Epigenomics Introduction
        11.5.4 BAYER AG Revenue in Personalized Medicine and Epigenomics Business (2016-2021)
        11.5.5 BAYER AG Recent Development
    11.6 Bio Vision
        11.6.1 Bio Vision Company Details
        11.6.2 Bio Vision Business Overview
        11.6.3 Bio Vision Personalized Medicine and Epigenomics Introduction
        11.6.4 Bio Vision Revenue in Personalized Medicine and Epigenomics Business (2016-2021)
        11.6.5 Bio Vision Recent Development
    11.7 Celgene Corp.
        11.7.1 Celgene Corp. Company Details
        11.7.2 Celgene Corp. Business Overview
        11.7.3 Celgene Corp. Personalized Medicine and Epigenomics Introduction
        11.7.4 Celgene Corp. Revenue in Personalized Medicine and Epigenomics Business (2016-2021)
        11.7.5 Celgene Corp. Recent Development
    11.8 Emd Millipore
        11.8.1 Emd Millipore Company Details
        11.8.2 Emd Millipore Business Overview
        11.8.3 Emd Millipore Personalized Medicine and Epigenomics Introduction
        11.8.4 Emd Millipore Revenue in Personalized Medicine and Epigenomics Business (2016-2021)
        11.8.5 Emd Millipore Recent Development
    11.9 Epigenomics AG
        11.9.1 Epigenomics AG Company Details
        11.9.2 Epigenomics AG Business Overview
        11.9.3 Epigenomics AG Personalized Medicine and Epigenomics Introduction
        11.9.4 Epigenomics AG Revenue in Personalized Medicine and Epigenomics Business (2016-2021)
        11.9.5 Epigenomics AG Recent Development
    11.10 Epigentex
        11.10.1 Epigentex Company Details
        11.10.2 Epigentex Business Overview
        11.10.3 Epigentex Personalized Medicine and Epigenomics Introduction
        11.10.4 Epigentex Revenue in Personalized Medicine and Epigenomics Business (2016-2021)
        11.10.5 Epigentex Recent Development
    11.11 Envivo Pharmaceuticals (Forum Pharmaceutricals)
        11.11.1 Envivo Pharmaceuticals (Forum Pharmaceutricals) Company Details
        11.11.2 Envivo Pharmaceuticals (Forum Pharmaceutricals) Business Overview
        11.11.3 Envivo Pharmaceuticals (Forum Pharmaceutricals) Personalized Medicine and Epigenomics Introduction
        11.11.4 Envivo Pharmaceuticals (Forum Pharmaceutricals) Revenue in Personalized Medicine and Epigenomics Business (2016-2021)
        11.11.5 Envivo Pharmaceuticals (Forum Pharmaceutricals) Recent Development
    11.12 Gilead Sciences
        11.12.1 Gilead Sciences Company Details
        11.12.2 Gilead Sciences Business Overview
        11.12.3 Gilead Sciences Personalized Medicine and Epigenomics Introduction
        11.12.4 Gilead Sciences Revenue in Personalized Medicine and Epigenomics Business (2016-2021)
        11.12.5 Gilead Sciences Recent Development
    11.13 Glaxosmithkline
        11.13.1 Glaxosmithkline Company Details
        11.13.2 Glaxosmithkline Business Overview
        11.13.3 Glaxosmithkline Personalized Medicine and Epigenomics Introduction
        11.13.4 Glaxosmithkline Revenue in Personalized Medicine and Epigenomics Business (2016-2021)
        11.13.5 Glaxosmithkline Recent Development
    11.14 Illumina Inc.
        11.14.1 Illumina Inc. Company Details
        11.14.2 Illumina Inc. Business Overview
        11.14.3 Illumina Inc. Personalized Medicine and Epigenomics Introduction
        11.14.4 Illumina Inc. Revenue in Personalized Medicine and Epigenomics Business (2016-2021)
        11.14.5 Illumina Inc. Recent Development
    11.15 Johnson & Johnson
        11.15.1 Johnson & Johnson Company Details
        11.15.2 Johnson & Johnson Business Overview
        11.15.3 Johnson & Johnson Personalized Medicine and Epigenomics Introduction
        11.15.4 Johnson & Johnson Revenue in Personalized Medicine and Epigenomics Business (2016-2021)
        11.15.5 Johnson & Johnson Recent Development
    11.16 Karus Therapeutics Limited
        11.16.1 Karus Therapeutics Limited Company Details
        11.16.2 Karus Therapeutics Limited Business Overview
        11.16.3 Karus Therapeutics Limited Personalized Medicine and Epigenomics Introduction
        11.16.4 Karus Therapeutics Limited Revenue in Personalized Medicine and Epigenomics Business (2016-2021)
        11.16.5 Karus Therapeutics Limited Recent Development
    11.17 Laboratory Corp. Of America Holdings
        11.17.1 Laboratory Corp. Of America Holdings Company Details
        11.17.2 Laboratory Corp. Of America Holdings Business Overview
        11.17.3 Laboratory Corp. Of America Holdings Personalized Medicine and Epigenomics Introduction
        11.17.4 Laboratory Corp. Of America Holdings Revenue in Personalized Medicine and Epigenomics Business (2016-2021)
        11.17.5 Laboratory Corp. Of America Holdings Recent Development
    11.18 LES Laboratoires Servier
        11.18.1 LES Laboratoires Servier Company Details
        11.18.2 LES Laboratoires Servier Business Overview
        11.18.3 LES Laboratoires Servier Personalized Medicine and Epigenomics Introduction
        11.18.4 LES Laboratoires Servier Revenue in Personalized Medicine and Epigenomics Business (2016-2021)
        11.18.5 LES Laboratoires Servier Recent Development
    11.18 Merck
        11.25.1 Merck Company Details
        11.25.2 Merck Business Overview
        11.25.3 Merck Personalized Medicine and Epigenomics Introduction
        11.25.4 Merck Revenue in Personalized Medicine and Epigenomics Business (2016-2021)
        11.25.5 Merck Recent Development
    11.20 Naturewise Biotech & Medicals Corp.
        11.20.1 Naturewise Biotech & Medicals Corp. Company Details
        11.20.2 Naturewise Biotech & Medicals Corp. Business Overview
        11.20.3 Naturewise Biotech & Medicals Corp. Personalized Medicine and Epigenomics Introduction
        11.20.4 Naturewise Biotech & Medicals Corp. Revenue in Personalized Medicine and Epigenomics Business (2016-2021)
        11.20.5 Naturewise Biotech & Medicals Corp. Recent Development
    11.21 Novartis Pharma AG
        11.21.1 Novartis Pharma AG Company Details
        11.21.2 Novartis Pharma AG Business Overview
        11.21.3 Novartis Pharma AG Personalized Medicine and Epigenomics Introduction
        11.21.4 Novartis Pharma AG Revenue in Personalized Medicine and Epigenomics Business (2016-2021)
        11.21.5 Novartis Pharma AG Recent Development
    11.22 Oncolys Biopharma Inc.
        11.22.1 Oncolys Biopharma Inc. Company Details
        11.22.2 Oncolys Biopharma Inc. Business Overview
        11.22.3 Oncolys Biopharma Inc. Personalized Medicine and Epigenomics Introduction
        11.22.4 Oncolys Biopharma Inc. Revenue in Personalized Medicine and Epigenomics Business (2016-2021)
        11.22.5 Oncolys Biopharma Inc. Recent Development
    11.23 Orchid Chemicals & Pharmaceuticals Limited
        11.23.1 Orchid Chemicals & Pharmaceuticals Limited Company Details
        11.23.2 Orchid Chemicals & Pharmaceuticals Limited Business Overview
        11.23.3 Orchid Chemicals & Pharmaceuticals Limited Personalized Medicine and Epigenomics Introduction
        11.23.4 Orchid Chemicals & Pharmaceuticals Limited Revenue in Personalized Medicine and Epigenomics Business (2016-2021)
        11.23.5 Orchid Chemicals & Pharmaceuticals Limited Recent Development
    11.24 Progen Pharmaceuticals Limited
        11.24.1 Progen Pharmaceuticals Limited Company Details
        11.24.2 Progen Pharmaceuticals Limited Business Overview
        11.24.3 Progen Pharmaceuticals Limited Personalized Medicine and Epigenomics Introduction
        11.24.4 Progen Pharmaceuticals Limited Revenue in Personalized Medicine and Epigenomics Business (2016-2021)
        11.24.5 Progen Pharmaceuticals Limited Recent Development
    11.25 Quest Diagnostics
        11.25.1 Quest Diagnostics Company Details
        11.25.2 Quest Diagnostics Business Overview
        11.25.3 Quest Diagnostics Personalized Medicine and Epigenomics Introduction
        11.25.4 Quest Diagnostics Revenue in Personalized Medicine and Epigenomics Business (2016-2021)
        11.25.5 Quest Diagnostics Recent Development
    11.26 Roche Holding AG
        11.26.1 Roche Holding AG Company Details
        11.26.2 Roche Holding AG Business Overview
        11.26.3 Roche Holding AG Personalized Medicine and Epigenomics Introduction
        11.26.4 Roche Holding AG Revenue in Personalized Medicine and Epigenomics Business (2016-2021)
        11.26.5 Roche Holding AG Recent Development
    11.27 Rubicon Genomics
        11.27.1 Rubicon Genomics Company Details
        11.27.2 Rubicon Genomics Business Overview
        11.27.3 Rubicon Genomics Personalized Medicine and Epigenomics Introduction
        11.27.4 Rubicon Genomics Revenue in Personalized Medicine and Epigenomics Business (2016-2021)
        11.27.5 Rubicon Genomics Recent Development
    11.28 Takeda Pharmaceutical Company Limited
        11.28.1 Takeda Pharmaceutical Company Limited Company Details
        11.28.2 Takeda Pharmaceutical Company Limited Business Overview
        11.28.3 Takeda Pharmaceutical Company Limited Personalized Medicine and Epigenomics Introduction
        11.28.4 Takeda Pharmaceutical Company Limited Revenue in Personalized Medicine and Epigenomics Business (2016-2021)
        11.28.5 Takeda Pharmaceutical Company Limited Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix
    13.1 Research Methodology
        13.1.1 Methodology/Research Approach
        13.1.2 Data Source
    13.2 Disclaimer
    13.3 Author Details
List of Tables
    Table 1. Global Personalized Medicine and Epigenomics Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
    Table 2. Key Players of Reagents
    Table 3. Key Players of Kits
    Table 4. Key Players of Instruments
    Table 5. Key Players of Enzymes
    Table 6. Key Players of Services
    Table 7. Global Personalized Medicine and Epigenomics Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
    Table 8. Global Personalized Medicine and Epigenomics Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
    Table 9. Global Personalized Medicine and Epigenomics Market Size by Regions (2016-2021) & (US$ Million)
    Table 10. Global Personalized Medicine and Epigenomics Market Share by Regions (2016-2021)
    Table 11. Global Personalized Medicine and Epigenomics Forecasted Market Size by Regions (2022-2027) & (US$ Million)
    Table 12. Global Personalized Medicine and Epigenomics Market Share by Regions (2022-2027)
    Table 13. Personalized Medicine and Epigenomics Market Trends
    Table 14. Personalized Medicine and Epigenomics Market Drivers
    Table 15. Personalized Medicine and Epigenomics Market Challenges
    Table 16. Personalized Medicine and Epigenomics Market Restraints
    Table 17. Global Personalized Medicine and Epigenomics Revenue by Players (2016-2021) & (US$ Million)
    Table 18. Global Personalized Medicine and Epigenomics Market Share by Players (2016-2021)
    Table 19. Global Top Personalized Medicine and Epigenomics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Personalized Medicine and Epigenomics as of 2020)
    Table 20. Ranking of Global Top Personalized Medicine and Epigenomics Companies by Revenue (US$ Million) in 2020
    Table 21. Global 5 Largest Players Market Share by Personalized Medicine and Epigenomics Revenue (CR5 and HHI) & (2016-2021)
    Table 22. Key Players Headquarters and Area Served
    Table 23. Key Players Personalized Medicine and Epigenomics Product Solution and Service
    Table 24. Date of Enter into Personalized Medicine and Epigenomics Market
    Table 25. Mergers & Acquisitions, Expansion Plans
    Table 26. Global Personalized Medicine and Epigenomics Market Size by Type (2016-2021) (US$ Million)
    Table 27. Global Personalized Medicine and Epigenomics Revenue Market Share by Type (2016-2021)
    Table 28. Global Personalized Medicine and Epigenomics Forecasted Market Size by Type (2022-2027) (US$ Million)
    Table 29. Global Personalized Medicine and Epigenomics Revenue Market Share by Type (2022-2027) & (US$ Million)
    Table 30. Global Personalized Medicine and Epigenomics Market Size Share by Application (2016-2021) & (US$ Million)
    Table 31. Global Personalized Medicine and Epigenomics Revenue Market Share by Application (2016-2021)
    Table 32. Global Personalized Medicine and Epigenomics Forecasted Market Size by Application (2022-2027) (US$ Million)
    Table 33. Global Personalized Medicine and Epigenomics Revenue Market Share by Application (2022-2027) & (US$ Million)
    Table 34. North America Personalized Medicine and Epigenomics Market Size by Type (2016-2021) (US$ Million)
    Table 35. North America Personalized Medicine and Epigenomics Market Size by Type (2022-2027) & (US$ Million)
    Table 36. North America Personalized Medicine and Epigenomics Market Size by Application (2016-2021) (US$ Million)
    Table 37. North America Personalized Medicine and Epigenomics Market Size by Application (2022-2027) & (US$ Million)
    Table 38. North America Personalized Medicine and Epigenomics Market Size by Country (2016-2021) & (US$ Million) 
    Table 39. North America Personalized Medicine and Epigenomics Market Size by Country (2022-2027) & (US$ Million) 
    Table 40. Europe Personalized Medicine and Epigenomics Market Size by Type (2016-2021) (US$ Million)
    Table 41. Europe Personalized Medicine and Epigenomics Market Size by Type (2022-2027) & (US$ Million)
    Table 42. Europe Personalized Medicine and Epigenomics Market Size by Application (2016-2021) (US$ Million)
    Table 43. Europe Personalized Medicine and Epigenomics Market Size by Application (2022-2027) & (US$ Million)
    Table 44. Europe Personalized Medicine and Epigenomics Market Size by Country (2016-2021) & (US$ Million) 
    Table 45. Europe Personalized Medicine and Epigenomics Market Size by Country (2022-2027) & (US$ Million) 
    Table 46. Asia-Pacific Personalized Medicine and Epigenomics Market Size by Type (2016-2021) (US$ Million)
    Table 47. Asia-Pacific Personalized Medicine and Epigenomics Market Size by Type (2022-2027) & (US$ Million)
    Table 48. Asia-Pacific Personalized Medicine and Epigenomics Market Size by Application (2016-2021) (US$ Million)
    Table 49. Asia-Pacific Personalized Medicine and Epigenomics Market Size by Application (2022-2027) & (US$ Million)
    Table 50. Asia-Pacific Personalized Medicine and Epigenomics Market Size by Region (2016-2021) & (US$ Million) 
    Table 51. Asia-Pacific Personalized Medicine and Epigenomics Market Size by Region (2022-2027) & (US$ Million) 
    Table 52. Latin America Personalized Medicine and Epigenomics Market Size by Type (2016-2021) (US$ Million)
    Table 53. Latin America Personalized Medicine and Epigenomics Market Size by Type (2022-2027) & (US$ Million)
    Table 54. Latin America Personalized Medicine and Epigenomics Market Size by Application (2016-2021) (US$ Million)
    Table 55. Latin America Personalized Medicine and Epigenomics Market Size by Application (2022-2027) & (US$ Million)
    Table 56. Latin America Personalized Medicine and Epigenomics Market Size by Country (2016-2021) & (US$ Million) 
    Table 57. Latin America Personalized Medicine and Epigenomics Market Size by Country (2022-2027) & (US$ Million) 
    Table 58. Middle East & Africa Personalized Medicine and Epigenomics Market Size by Type (2016-2021) (US$ Million)
    Table 59. Middle East & Africa Personalized Medicine and Epigenomics Market Size by Type (2022-2027) & (US$ Million)
    Table 60. Middle East & Africa Personalized Medicine and Epigenomics Market Size by Application (2016-2021) (US$ Million)
    Table 61. Middle East & Africa Personalized Medicine and Epigenomics Market Size by Application (2022-2027) & (US$ Million)
    Table 62. Middle East & Africa Personalized Medicine and Epigenomics Market Size by Country (2016-2021) & (US$ Million) 
    Table 63. Middle East & Africa Personalized Medicine and Epigenomics Market Size by Country (2022-2027) & (US$ Million) 
    Table 64. Abbott Laboratories Company Details
    Table 65. Abbott Laboratories Business Overview
    Table 66. Abbott Laboratories Personalized Medicine and Epigenomics Product
    Table 67. Abbott Laboratories Revenue in Personalized Medicine and Epigenomics Business (2016-2021) & (US$ Million)
    Table 68. Abbott Laboratories Recent Development
    Table 69. Affymetrix Company Details
    Table 70. Affymetrix Business Overview
    Table 71. Affymetrix Personalized Medicine and Epigenomics Product
    Table 72. Affymetrix Revenue in Personalized Medicine and Epigenomics Business (2016-2021) & (US$ Million)
    Table 73. Affymetrix Recent Development
    Table 74. Agilent Technologies Company Details
    Table 75. Agilent Technologies Business Overview
    Table 76. Agilent Technologies Personalized Medicine and Epigenomics Product
    Table 77. Agilent Technologies Revenue in Personalized Medicine and Epigenomics Business (2016-2021) & (US$ Million)
    Table 78. Agilent Technologies Recent Development
    Table 79. Astellas Pharmaceuticals Company Details
    Table 80. Astellas Pharmaceuticals Business Overview
    Table 81. Astellas Pharmaceuticals Personalized Medicine and Epigenomics Product
    Table 82. Astellas Pharmaceuticals Revenue in Personalized Medicine and Epigenomics Business (2016-2021) & (US$ Million)
    Table 83. Astellas Pharmaceuticals Recent Development
    Table 84. BAYER AG Company Details
    Table 85. BAYER AG Business Overview
    Table 86. BAYER AG Personalized Medicine and Epigenomics Product
    Table 87. BAYER AG Revenue in Personalized Medicine and Epigenomics Business (2016-2021) & (US$ Million)
    Table 88. BAYER AG Recent Development
    Table 89. Bio Vision Company Details
    Table 90. Bio Vision Business Overview
    Table 91. Bio Vision Personalized Medicine and Epigenomics Product
    Table 92. Bio Vision Revenue in Personalized Medicine and Epigenomics Business (2016-2021) & (US$ Million)
    Table 93. Bio Vision Recent Development
    Table 94. Celgene Corp. Company Details
    Table 95. Celgene Corp. Business Overview
    Table 96. Celgene Corp. Personalized Medicine and Epigenomics Product
    Table 97. Celgene Corp. Revenue in Personalized Medicine and Epigenomics Business (2016-2021) & (US$ Million)
    Table 98. Celgene Corp. Recent Development
    Table 99. Emd Millipore Company Details
    Table 100. Emd Millipore Business Overview
    Table 101. Emd Millipore Revenue in Personalized Medicine and Epigenomics Business (2016-2021) & (US$ Million)
    Table 102. Emd Millipore Recent Development
    Table 103. Epigenomics AG Company Details
    Table 104. Epigenomics AG Business Overview
    Table 105. Epigenomics AG Personalized Medicine and Epigenomics Product
    Table 106. Epigenomics AG Revenue in Personalized Medicine and Epigenomics Business (2016-2021) & (US$ Million)
    Table 107. Epigenomics AG Recent Development
    Table 108. Epigentex Company Details
    Table 109. Epigentex Business Overview
    Table 110. Epigentex Personalized Medicine and Epigenomics Product
    Table 111. Epigentex Revenue in Personalized Medicine and Epigenomics Business (2016-2021) & (US$ Million)
    Table 112. Epigentex Recent Development
    Table 113. Envivo Pharmaceuticals (Forum Pharmaceutricals) Company Details
    Table 114. Envivo Pharmaceuticals (Forum Pharmaceutricals) Business Overview
    Table 115. Envivo Pharmaceuticals (Forum Pharmaceutricals) Personalized Medicine and Epigenomics Product
    Table 116. Envivo Pharmaceuticals (Forum Pharmaceutricals) Revenue in Personalized Medicine and Epigenomics Business (2016-2021) & (US$ Million)
    Table 117. Envivo Pharmaceuticals (Forum Pharmaceutricals) Recent Development
    Table 118. Gilead Sciences Company Details
    Table 119. Gilead Sciences Business Overview
    Table 120. Gilead Sciences Personalized Medicine and Epigenomics Product
    Table 121. Gilead Sciences Revenue in Personalized Medicine and Epigenomics Business (2016-2021) & (US$ Million)
    Table 122. Gilead Sciences Recent Development
    Table 123. Glaxosmithkline Company Details
    Table 124. Glaxosmithkline Business Overview
    Table 125. Glaxosmithkline Personalized Medicine and Epigenomics Product
    Table 126. Glaxosmithkline Revenue in Personalized Medicine and Epigenomics Business (2016-2021) & (US$ Million)
    Table 127. Glaxosmithkline Recent Development
    Table 128. Illumina Inc. Company Details
    Table 129. Illumina Inc. Business Overview
    Table 130. Illumina Inc. Personalized Medicine and Epigenomics Product
    Table 131. Illumina Inc. Revenue in Personalized Medicine and Epigenomics Business (2016-2021) & (US$ Million)
    Table 132. Illumina Inc. Recent Development
    Table 133. Johnson & Johnson Company Details
    Table 134. Johnson & Johnson Business Overview
    Table 135. Johnson & Johnson Personalized Medicine and Epigenomics Product
    Table 136. Johnson & Johnson Revenue in Personalized Medicine and Epigenomics Business (2016-2021) & (US$ Million)
    Table 137. Johnson & Johnson Recent Development
    Table 138. Karus Therapeutics Limited Company Details
    Table 139. Karus Therapeutics Limited Business Overview
    Table 140. Karus Therapeutics Limited Personalized Medicine and Epigenomics Product
    Table 141. Karus Therapeutics Limited Revenue in Personalized Medicine and Epigenomics Business (2016-2021) & (US$ Million)
    Table 142. Karus Therapeutics Limited Recent Development
    Table 143. Laboratory Corp. Of America Holdings Company Details
    Table 144. Laboratory Corp. Of America Holdings Business Overview
    Table 145. Laboratory Corp. Of America Holdings Personalized Medicine and Epigenomics Product
    Table 146. Laboratory Corp. Of America Holdings Revenue in Personalized Medicine and Epigenomics Business (2016-2021) & (US$ Million)
    Table 147. Laboratory Corp. Of America Holdings Recent Development
    Table 148. LES Laboratoires Servier Company Details
    Table 149. LES Laboratoires Servier Business Overview
    Table 150. LES Laboratoires Servier Personalized Medicine and Epigenomics Product
    Table 151. LES Laboratoires Servier Revenue in Personalized Medicine and Epigenomics Business (2016-2021) & (US$ Million)
    Table 152. LES Laboratoires Servier Recent Development
    Table 153. Merck Company Details
    Table 154. Merck Business Overview
    Table 155. Merck Personalized Medicine and Epigenomics Product
    Table 156. Merck Revenue in Personalized Medicine and Epigenomics Business (2016-2021) & (US$ Million)
    Table 157. Merck Recent Development
    Table 158. Naturewise Biotech & Medicals Corp. Company Details
    Table 159. Naturewise Biotech & Medicals Corp. Business Overview
    Table 160. Naturewise Biotech & Medicals Corp. Personalized Medicine and Epigenomics Product
    Table 161. Naturewise Biotech & Medicals Corp. Revenue in Personalized Medicine and Epigenomics Business (2016-2021) & (US$ Million)
    Table 162. Naturewise Biotech & Medicals Corp. Recent Development
    Table 163. Novartis Pharma AG Company Details
    Table 164. Novartis Pharma AG Business Overview
    Table 165. Novartis Pharma AG Personalized Medicine and Epigenomics Product
    Table 166. Novartis Pharma AG Revenue in Personalized Medicine and Epigenomics Business (2016-2021) & (US$ Million)
    Table 167. Novartis Pharma AG Recent Development
    Table 168. Oncolys Biopharma Inc. Company Details
    Table 169. Oncolys Biopharma Inc. Business Overview
    Table 170. Oncolys Biopharma Inc. Personalized Medicine and Epigenomics Product
    Table 171. Oncolys Biopharma Inc. Revenue in Personalized Medicine and Epigenomics Business (2016-2021) & (US$ Million)
    Table 172. Oncolys Biopharma Inc. Recent Development
    Table 173. Orchid Chemicals & Pharmaceuticals Limited Company Details
    Table 174. Orchid Chemicals & Pharmaceuticals Limited Business Overview
    Table 175. Orchid Chemicals & Pharmaceuticals Limited Personalized Medicine and Epigenomics Product
    Table 176. Orchid Chemicals & Pharmaceuticals Limited Revenue in Personalized Medicine and Epigenomics Business (2016-2021) & (US$ Million)
    Table 177. Orchid Chemicals & Pharmaceuticals Limited Recent Development
    Table 178. Progen Pharmaceuticals Limited Company Details
    Table 179. Progen Pharmaceuticals Limited Business Overview
    Table 180. Progen Pharmaceuticals Limited Personalized Medicine and EpigenomicsProduct
    Table 181. Progen Pharmaceuticals Limited Revenue in Personalized Medicine and Epigenomics Business (2016-2021) & (US$ Million)
    Table 182. Progen Pharmaceuticals Limited Recent Development
    Table 183. Quest Diagnostics Company Details
    Table 184. Quest Diagnostics Business Overview
    Table 185. Quest Diagnostics Personalized Medicine and Epigenomics Product
    Table 186. Quest Diagnostics Revenue in Personalized Medicine and Epigenomics Business (2016-2021) & (US$ Million)
    Table 187. Quest Diagnostics Recent Development
    Table 188. Roche Holding AG Company Details
    Table 189. Roche Holding AG Business Overview
    Table 190. Roche Holding AG Personalized Medicine and Epigenomics Product
    Table 191. Roche Holding AG Revenue in Personalized Medicine and Epigenomics Business (2016-2021) & (US$ Million)
    Table 192. Roche Holding AG Recent Development
    Table 193. Rubicon Genomics Company Details
    Table 194. Rubicon Genomics Business Overview
    Table 195. Rubicon Genomics Personalized Medicine and Epigenomics Product
    Table 196. Rubicon Genomics Revenue in Personalized Medicine and Epigenomics Business (2016-2021) & (US$ Million)
    Table 197. Rubicon Genomics Recent Development
    Table 198. Takeda Pharmaceutical Company Limited Company Details
    Table 199. Takeda Pharmaceutical Company Limited Business Overview
    Table 200. Takeda Pharmaceutical Company Limited Personalized Medicine and Epigenomics Product
    Table 201. Takeda Pharmaceutical Company Limited Revenue in Personalized Medicine and Epigenomics Business (2016-2021) & (US$ Million)
    Table 202. Takeda Pharmaceutical Company Limited Recent Development
    Table 203. Research Programs/Design for This Report
    Table 204. Key Data Information from Secondary Sources
    Table 205. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Personalized Medicine and Epigenomics Market Share by Type: 2020 VS 2027
    Figure 2. Reagents Features
    Figure 3. Kits Features
    Figure 4. Instruments Features
    Figure 5. Enzymes Features
    Figure 6. Services Features
    Figure 7. Global Personalized Medicine and Epigenomics Market Share by Application: 2020 VS 2027
    Figure 8. Oncology Case Studies
    Figure 9. Non-Oncology Case Studies
    Figure 10. Cancer Drug Technology Case Studies
    Figure 11. Personalized Medicine and Epigenomics Report Years Considered
    Figure 12. Global Personalized Medicine and Epigenomics Market Size (US$ Million), Year-over-Year: 2016-2027
    Figure 13. Global Personalized Medicine and Epigenomics Market Size (US$ Million), 2016 VS 2021 VS 2027
    Figure 14. Global Personalized Medicine and Epigenomics Market Share by Regions: 2020 VS 2027
    Figure 15. Global Personalized Medicine and Epigenomics Market Share by Regions (2022-2027)
    Figure 16. Global Personalized Medicine and Epigenomics Market Share by Players in 2020
    Figure 17. Global Top Personalized Medicine and Epigenomics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Personalized Medicine and Epigenomics as of 2020
    Figure 18. The Top 10 and 5 Players Market Share by Personalized Medicine and Epigenomics Revenue in 2020
    Figure 19. Global Personalized Medicine and Epigenomics Revenue Market Share by Type (2016-2021)
    Figure 20. Global Personalized Medicine and Epigenomics Revenue Market Share by Type (2022-2027)
    Figure 21. North America Personalized Medicine and Epigenomics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 22. North America Personalized Medicine and Epigenomics Market Share by Type (2016-2027)
    Figure 23. North America Personalized Medicine and Epigenomics Market Share by Application (2016-2027)
    Figure 24. North America Personalized Medicine and Epigenomics Market Share by Country (2016-2027)
    Figure 25. United States Personalized Medicine and Epigenomics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 26. Canada Personalized Medicine and Epigenomics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 27. Europe Personalized Medicine and Epigenomics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 28. Europe Personalized Medicine and Epigenomics Market Share by Type (2016-2027)
    Figure 29. Europe Personalized Medicine and Epigenomics Market Share by Application (2016-2027)
    Figure 30. Europe Personalized Medicine and Epigenomics Market Share by Country (2016-2027)
    Figure 31. Germany Personalized Medicine and Epigenomics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 32. France Personalized Medicine and Epigenomics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 33. U.K. Personalized Medicine and Epigenomics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 34. Italy Personalized Medicine and Epigenomics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 35. Russia Personalized Medicine and Epigenomics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 36. Nordic Personalized Medicine and Epigenomics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 37. Asia-Pacific Personalized Medicine and Epigenomics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 38. Asia-Pacific Personalized Medicine and Epigenomics Market Share by Type (2016-2027)
    Figure 39. Asia-Pacific Personalized Medicine and Epigenomics Market Share by Application (2016-2027)
    Figure 40. Asia-Pacific Personalized Medicine and Epigenomics Market Share by Region (2016-2027)
    Figure 41. China Personalized Medicine and Epigenomics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 42. Japan Personalized Medicine and Epigenomics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 43. South Korea Personalized Medicine and Epigenomics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 44. Southeast Asia Personalized Medicine and Epigenomics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 45. India Personalized Medicine and Epigenomics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 46. Australia Personalized Medicine and Epigenomics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 47. Latin America Personalized Medicine and Epigenomics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 48. Latin America Personalized Medicine and Epigenomics Market Share by Type (2016-2027)
    Figure 49. Latin America Personalized Medicine and Epigenomics Market Share by Application (2016-2027)
    Figure 50. Latin America Personalized Medicine and Epigenomics Market Share by Country (2016-2027)
    Figure 51. Mexico Personalized Medicine and Epigenomics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 52. Brazil Personalized Medicine and Epigenomics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 53. Middle East & Africa Personalized Medicine and Epigenomics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 54. Middle East & Africa Personalized Medicine and Epigenomics Market Share by Type (2016-2027)
    Figure 55. Middle East & Africa Personalized Medicine and Epigenomics Market Share by Application (2016-2027)
    Figure 56. Middle East & Africa Personalized Medicine and Epigenomics Market Share by Country (2016-2027)
    Figure 57. Turkey Personalized Medicine and Epigenomics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 58. Saudi Arabia Personalized Medicine and Epigenomics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 59. UAE Personalized Medicine and Epigenomics Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 60. Abbott Laboratories Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2016-2021)
    Figure 61. Affymetrix Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2016-2021)
    Figure 62. Agilent Technologies Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2016-2021)
    Figure 63. Astellas Pharmaceuticals Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2016-2021)
    Figure 64. BAYER AG Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2016-2021)
    Figure 65. Bio Vision Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2016-2021)
    Figure 66. Celgene Corp. Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2016-2021)
    Figure 67. Emd Millipore Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2016-2021)
    Figure 68. Epigenomics AG Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2016-2021)
    Figure 69. Epigentex Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2016-2021)
    Figure 70. Envivo Pharmaceuticals (Forum Pharmaceutricals) Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2016-2021)
    Figure 71. Gilead Sciences Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2016-2021)
    Figure 72. Glaxosmithkline Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2016-2021)
    Figure 73. Illumina Inc. Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2016-2021)
    Figure 74. Johnson & Johnson Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2016-2021)
    Figure 75. Karus Therapeutics Limited Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2016-2021)
    Figure 76. Laboratory Corp. Of America Holdings Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2016-2021)
    Figure 77. LES Laboratoires Servier Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2016-2021)
    Figure 78. Merck Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2016-2021)
    Figure 79. Naturewise Biotech & Medicals Corp. Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2016-2021)
    Figure 80. Novartis Pharma AG Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2016-2021)
    Figure 81. Oncolys Biopharma Inc. Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2016-2021)
    Figure 82. Orchid Chemicals & Pharmaceuticals Limited Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2016-2021)
    Figure 83. Progen Pharmaceuticals Limited Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2016-2021)
    Figure 84. Quest Diagnostics Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2016-2021)
    Figure 85. Roche Holding AG Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2016-2021)
    Figure 86. Rubicon Genomics Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2016-2021)
    Figure 87. Takeda Pharmaceutical Company Limited Revenue Growth Rate in Personalized Medicine and Epigenomics Business (2016-2021)
    Figure 88. Bottom-up and Top-down Approaches for This Report
    Figure 89. Data Triangulation
    Figure 90. Key Executives Interviewed
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
Abbott Laboratories
Affymetrix
Agilent Technologies
Astellas Pharmaceuticals
BAYER AG
Bio Vision
Celgene Corp.
Emd Millipore
Epigenomics AG
Epigentex
Envivo Pharmaceuticals (Forum Pharmaceutricals)
Gilead Sciences
Glaxosmithkline
Illumina Inc.
Johnson & Johnson
Karus Therapeutics Limited
Laboratory Corp. Of America Holdings
LES Laboratoires Servier
Merck
Naturewise Biotech & Medicals Corp.
Novartis Pharma AG
Oncolys Biopharma Inc.
Orchid Chemicals & Pharmaceuticals Limited
Progen Pharmaceuticals Limited
Quest Diagnostics
Roche Holding AG
Rubicon Genomics
Takeda Pharmaceutical Company Limited
Frequently Asked Questions
Personalized Medicine and Epigenomics report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
Personalized Medicine and Epigenomics report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
Personalized Medicine and Epigenomics report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.

Related Reports